Naming more names.

Henchmen and henchwomen of the Oligarchs Culling Shit (TM/Sage Hana Productions)

Jordan Schachtel’s recent reporting about Dr. Terry Adirim, MD, MPH, MBA, as a medical officer within the Department of Defense instrumental in the military cull for her memo defining EUA products and Comirnaty as “interchangable,” and the marking of the 75th anniversary of the Nuremberg Code derived from the Doctors Trial — including Holocaust survivor Vera Sharav’s speech (transcript) — reminded me of that layer of culpable actors in the Department of Health and Human Services.

These men and women comprise one of the administrative tiers of the Oligarchs Culling Shit system, without whose original complicity the process could not have started, and without whose ongoing complicity it cannot continue.

They’re the Good Germans who make the trains to the concentration camps lines at the walk-in vaxx clinics run smoothly.

They’re more defendants for the federal criminal prosecutions that need to happen.

---

Some of the most horrific ethical abdications by researchers and physicians have occurred within the Food and Drug Administration, where Dr. Marion Gruber held signing authority for all three of the primary lethal injections EUA-authorized by teams of scientists.

Dr. Gruber’s title was Director of the Center for Biologics Evaluation and Research (CBER) Office of Vaccine Research and Review (OVRR), a position now occupied by Dr. Peter Marks, who is carrying forward Gruber’s lethal legacy.

Gruber resigned from her FDA position effective Nov. 1, 2021, and now works as Vice President for Public Health and Regulatory Science at IAVI, the International AIDS Vaccine Initiative, launched by the Rockefeller Foundation in 1994.

IAVI is funded by the Bill & Melinda Gates Foundation (BMGF), US Agency for International Development (USAID), World Bank, Coalition for Epidemic Preparedness and Innovation (CEPI), US Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA), National Institutes of Health (NIH), National Institutes of Allergies and Infectious Diseases (NIAID), US Department of Defense Congressionally Directed Medical Research Program, GlaxoSmithKline, Merck and other mass-murderous, anti-human global oligarchic institutions.

---

From the FDA’s Covid-19 Emergency Use Authorizations page:

• 2020/12/11 - Pfizer/BioNTech

• 2020/12/18 - Moderna

• 2021/02/27 - Janssen

Below are the names of the product reviewers — led by Marion Gruber — whose rendered scientific opinions gave the illusion of credibility and lawfulness to the propulsion of the lethal injections out of the laboratories and manufacturing facilities, into the trucks, across the highways, into the clinics, into the hands of the nurses, doctors and pharmacists, and into the bodies of hundreds of millions of people worldwide.

Acronym key at the footnote

¹

.

---

2020/12/11 - Emergency Use Authorization (EUA) for an Unapproved Product Review Memorandum - Pfizer BioNTech

• Marion Gruber, Ph.D., Director, CBER/OVRR, signatory authority

• Ramachandra Naik, Ph.D., Chair, OVRR/DVRPA

• Capt. Michael Smith, Ph.D., Regulatory Project Manager, OVRR/DVRPA

• Susan Wollersheim, M.D., Clinical reviewer, OVRR/DVRPA

• Nabil Al-Humadi, Ph.D., Toxicology reviewer, OVRR/DVRPA

• Lei Huang, Ph.D., Biostatistics reviewer, OBE/DB

• Haruhiko Murata, Ph.D., CMC/Product reviewer, OVRR/DVP

• Xiao Wang, Ph.D., CMC/Product reviewer, OVRR/DVP

• Laura Fontan, Ph.D., CMC/Facility reviewer; OCBQ/DMPQ

• Kathleen Jones, Ph.D., CMC/Facility reviewer, OCBQ/DMPQ

• Kerry Welsh, M.D., Pharmacovigilance reviewer, OBE/DE

• Narayan Nair, M.D., Pharmacovigilance reviewer, OBE/DE

• Brenda Baldwin, Ph.D., Data Integrity reviewer, OVRR/DVRPA

• Bhanumathi Kannan, Ph.D., BIMO reviewer, OCBQ/DIS/BMB

• Oluchi Elekwachi, Ph.D., Labeling reviewer, OCBQ/DCM/APLB

2020/12/18 - Emergency Use Authorization (EUA) for an Unapproved Product Review Memorandum - Moderna

• Marion Gruber, Ph.D., Director, CBER/OVRR, signatory authority

• Sudhakar Agnihothram, Ph.D., Chair, OVRR/DVRPA

• Goutam Sen, Ph.D., Regulatory Project Manager, OVRR/DVRPA

• Rachel Zhang, M.D., Clinical reviewer, OVRR/DVRPA

• Ching-Long Sun, Ph.D., Toxicology reviewer, OVRR/DVRPA

• Ye Yang, Ph.D., Biostatistics reviewer, OBE/DB;

• Alena Dabrazhynetskaya Ph.D., CMC/Product reviewer, OVRR/DVP

• Li-Sheng Fowler Ph.D., CMC/Product reviewer, OVRR/DVP

• Obinna Echeozo MPH, MBA, CMC/Facility reviewer; OCBQ/DMPQ

• Ekaterina Allen Ph.D., CMC/Facility reviewer; OCBQ/DMPQ

• Timothy Martin Ph.D., CMC/Facility reviewer; OCBQ/DMPQ;

• Jane Baumblatt M.D., Pharmacovigilance reviewer, OBE/DE;

• Daphne Stewart, Labeling reviewer, OVRR/DVRPA

• Brenda Baldwin Ph.D., Data Integrity reviewer, OVRR/DVRPA

• Christine Drabick M.S, BIMO reviewer, OCBQ/DIS/BMB

• Oluchi Elekwachi, Pharm.D., MPH, Labeling reviewer, OCBQ/DCM/APLB

2021/02/27 - Emergency Use Authorization (EUA) for an Unapproved Product Review Memorandum - Janssen

• Marion Gruber, Ph.D., Director, CBER/OVRR, signatory authority

• Bharat Khurana, DVM, Ph.D., MBA, Regulatory Project Manager, OVRR/DVRPA

• Sudhakar Agnihothram, Ph.D., Committee chair, OVRR/DVRPA

• Rachel Zhang, M.D., Clinical reviewer, OVRR/DVRPA

• Yosefa Hefter, M.D., Clinical reviewer, OVRR/DVRPA

• Claudia Wrzesinski, Ph.D., Toxicology reviewer, OVRR/DVRPA

• Ye Yang, Ph.D., Biostatistics reviewer, OBE/DB

• Lei Huang, Ph.D., Biostatistics reviewer, OBE/DB

• Marian Major, Ph.D., CMC/Product reviewer, OVRR/DVP

• Alla Kachko, Ph.D., CMC/Product reviewer, OVRR/DVP

• Pankaj (Pete) Amin, B.S., CMC/Facility reviewer; OCBQ/DMPQ

• Holly Brevig, Ph.D., CMC/Facility reviewer; OCBQ/DMPQ

• Jane Woo, M.D., Pharmacovigilance reviewer, OBE/DE

• Brenda Baldwin, Ph.D., Data Integrity reviewer, OVRR/DVRPA

• Haecin Chun, M.S., BIMO reviewer, OCBQ/DIS/BMB

• Bhanu Kannan, M.S., BIMO reviewer, OCBQ/DIS/BMB

• Oluchi Elekwachi, Pharm.D., MPH, Labeling reviewer, OCBQ/DCM/APLB

1. APLB - Advertising and Promotional Labeling Branch

BIMO - Bioresearch Monitoring Program

BMB -

CBER - Center for Biologics Evaluation and Research

CMC - Chemistry Manufacturing and Controls

DE -

DIS - Division of Inspections and Surveillance

DMPQ - Division of Manufacturing and Product Quality

DVP - Division of Viral Products

DVRPA - Division of Vaccines and Related Product Applications

OBE - Office of Biostatistics and Epidemiology

OCBQ - Office of Compliance and Biologics Quality

OVRR - Office of Vaccine Research and Review

---

St. Timothy and his grandmother. Rembrandt.